Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | RARB | P10826 | 3/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7333704 | 1.00 | SMPD1 (0.63) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL2356088 | 0.99 | SMPD1 (0.61) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL2350269 | 0.99 | SMPD1 (0.61) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL2351006 | 0.98 | SMPD1 (0.65) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL6132917 | 0.91 | SMPD1 (0.57) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL6132232 | 0.91 | SMPD1 (0.57) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL7333208 | 0.90 | SMPD1 (0.58) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL7403884 | 0.90 | RARB (0.64) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL2353533 | 0.90 | RARB (0.64) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL903875 | 0.90 | SMPD1 (0.61) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143749-A | Strain for high-yield FR901379 and construction method and application thereof | 中国科学院青岛生物能源与过程研究所 | 2023-12-01 | — | — | CN | disclosed |
| CN-114874919-A | Micafungin precursor FR901379 high-yield strain and application thereof | 中国科学院青岛生物能源与过程研究所 | 2022-08-09 | — | — | CN | disclosed |
| US-7199248-B2 | Process | ASTELLAS PHARMA INC. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20050227914-A1 | New process | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| WO-2004014879-A1 | NEW PROCESS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-19 | — | — | WO | disclosed |
| EP-0788511-B1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-12-11 | — | — | EP | disclosed |
| US-6455726-B2 | STARTING MATERIALS FOR FUNGICIDES OF LIPOPEPTIDE TYPE; ISOMER/IMPURITY FREE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-24 | — | — | US | disclosed |
| US-6291680-B1 | REACTING 1-AMINO-3-OXO-1-PROPENE DERIVATIVE WITH HYDROXYLAMINE SALT TO PROVIDE 4-(5-(4-PENTYLOXYPHENYL)-ISOXAZOL-3-YL)BENZOATE COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| US-6265536-B1 | MICROBIOCIDE AND FUNGICIDE WHICH IS INHIBITOR OF BETA-1,3-GLUCAN SYNTHASE; TREATMENT OF PNEUMOCYSTIS CARINII INFECTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| US-20010008943-A1 | Novel manufacturing method | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-07-19 | — | — | US | disclosed |
| US-6107458-A | FUNGICIDE WHICH IS BETA-1,3-GLYCAN SYNTHASE INHIBITOR; FOR PROPHYLAXIS AND TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS LIKE PNEUMONIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-22 | — | — | US | disclosed |
| EP-0994101-A1 | NEW PRODUCTION PROCESS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-19 | — | — | EP | disclosed |
| EP-0788511-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996011210-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227914-A1 | New process | CA2, AKR1C3, AGTR2 | SMPD1 2414/4885CYP1A2 5/4885CYP19A1 171/4885 |
| US-20010008943-A1 | Novel manufacturing method | ALKBH3, CMA1, ALKBH1 | SMPD1 1867/4885CYP1A2 44/4885CYP19A1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.